Comparative Pharmacology
Head-to-head clinical analysis: CEDAX versus CEFMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEDAX versus CEFMAX.
CEDAX vs CEFMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftibuten is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP 3, thereby inhibiting peptidoglycan cross-linking and leading to cell lysis.
CEFMAX (cefepime) is a fourth-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3 in Gram-negative bacteria and PBP-1a/1b in Gram-positive bacteria, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It has zwitterionic properties facilitating rapid penetration through Gram-negative outer membranes and is relatively resistant to hydrolysis by many beta-lactamases, including AmpC beta-lactamases.
400 mg orally once daily for 5-10 days.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
None Documented
None Documented
Terminal elimination half-life: 2.6-3.0 hours; prolonged in renal impairment (up to 10-15 hours in severe impairment)
2–4 hours in adults with normal renal function; prolonged to 20–40 hours in severe renal impairment (CrCl <10 mL/min).
Renal: 92-96% unchanged; biliary/fecal: <5%
Primarily renal (80–90% unchanged via glomerular filtration and tubular secretion); biliary/fecal elimination accounts for <5%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic